How Long Do Drug Patents Last in the US?

A US drug patent lasts 20 years from the filing date. But this number is misleading. Because drugs spend 8-12 years in development and clinical trials before FDA approval, the effective period of market exclusivity after a drug reaches patients is typically only 7-12 years. Several mechanisms can shorten or extend this window.

The Basic Term: 20 Years From Filing

Under US patent law (35 U.S.C. 154), utility patents are granted for a term of 20 years from the earliest filing date. This applies to all patents, not just pharmaceutical ones. The clock starts ticking when the patent application is filed with the USPTO, not when the patent is granted or when the drug reaches the market.

This is a critical distinction for pharmaceuticals. A drug company typically files its first patent early in the development process, often before clinical trials even begin. The years spent in Phase I, II, and III trials and the FDA review process all eat into the 20-year patent term.

The Timeline: Filing to Market

Here is how the 20-year patent term typically breaks down for a new drug:

In practice, the average new drug has about 7-12 years of effective patent-protected market exclusivity after FDA approval. This is the window during which the company earns back its R&D investment and generates profit.

Extensions That Add Time

Congress has created several mechanisms to compensate drug manufacturers for time lost during development and regulatory review:

Patent Term Extension (PTE)

Under the Hatch-Waxman Act of 1984, manufacturers can apply for a patent term extension of up to 5 years to compensate for time spent in clinical trials and FDA review. Only one patent per drug is eligible, and the total patent life after approval cannot exceed 14 years. PTE is the most common form of extension and applies to most new drugs.

Patent Term Adjustment (PTA)

If the USPTO takes longer than expected to examine a patent application (delays attributable to the patent office, not the applicant), the patent term is adjusted day-for-day to compensate. PTA can add months or even years to a patent term and is calculated automatically by the USPTO.

Pediatric Exclusivity

If a manufacturer conducts pediatric studies requested by the FDA, it receives 6 additional months of market exclusivity on all patents and exclusivities associated with that drug. This is not a patent extension per se but an exclusivity extension that delays generic competition by 6 months. It has been one of the most widely used incentives in pharmaceutical law.

Types of Regulatory Exclusivity

Beyond patents, the FDA grants several forms of regulatory exclusivity that independently block generic or biosimilar competition:

These exclusivity periods can overlap with patent terms or extend beyond them. The date that actually matters for generic entry is the later of patent expiration or exclusivity expiration, a concept known as loss of exclusivity (LOE).

Why Some Drugs Seem Protected for Decades

Drug companies routinely file dozens of patents on a single drug over time, covering not just the active molecule but also formulations, manufacturing processes, dosing methods, combination products, and specific therapeutic uses. Each patent has its own 20-year term starting from its own filing date. This layering, sometimes called a "patent thicket," can extend effective protection well beyond 20 years from the original filing. Humira (adalimumab), for example, accumulated over 130 patents before its final protections expired.

Frequently Asked Questions